Sirio Pharma Co.Ltd(300791) prior approval opinions of independent directors
Sirio Pharma Co.Ltd(300791) independent director
About the sixth meeting of the third board of directors of the company
Prior approval opinions on relevant matters
In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM, the articles of association of Sirio Pharma Co.Ltd(300791) and other relevant laws, regulations and rules, As an independent director of Sirio Pharma Co.Ltd(300791) (hereinafter referred to as “the company”), based on the principle of being responsible to the company and all shareholders, and based on the position of seeking truth from facts and independent judgment, we have fully reviewed the relevant matters of the sixth meeting of the third board of directors of the company and issued the following prior approval opinions:
1、 Prior approval opinions on re employment of audit institutions in 2021
Huaxing Certified Public Accountants (special general partnership) has the practice certificate of certified public accountants and the practice qualification of securities and futures related businesses, has the experience and ability to provide audit services for listed companies, and can provide fair, fair and independent audit services for the company. This appointment is based on the needs of the company’s business development, complies with relevant laws, regulations and the Sirio Pharma Co.Ltd(300791) articles of association, and does not damage the interests of the company and other shareholders, especially the interests of minority shareholders. Therefore, we unanimously approve and agree to submit the proposal on renewing the appointment of audit institutions in 2021 to the sixth meeting of the third board of directors of the company for deliberation.
2、 Prior approval opinions on the company’s expected daily connected transactions in 2022
The daily related party transactions between the company and Guangdong Ruichi Packaging Co., Ltd. are conducted due to the needs of normal production and operation, and the transaction price is determined according to the fair market price. There is no damage to the interests of the company and all shareholders, which is in line with the relevant provisions of relevant laws and regulations such as the Listing Rules of gem shares of Shenzhen Stock Exchange. We unanimously approved and agreed to submit the proposal on the company’s expected daily connected transactions in 2022 to the sixth meeting of the third board of directors for deliberation, and the connected directors should avoid voting on this matter.
Sirio Pharma Co.Ltd(300791) prior approval opinions of independent directors
(there is no text below, which is the signature page of the pre approval opinions on relevant matters of the sixth meeting of the third board of directors of Sirio Pharma Co.Ltd(300791) independent directors)
Sirio Pharma Co.Ltd(300791) prior approval opinions of independent directors
(this page is the signature page of Sirio Pharma Co.Ltd(300791) independent directors’ prior approval opinions on relevant matters of the sixth meeting of the third board of directors)
Signature of independent director:
GUI Long Zhu
Hu Shiming
High opinion
January 24, 2002
